Literature DB >> 21874254

MHC class II genotype- and MHC class I and II phenotype-related parameters in sporadic colorectal cancer.

Toralf Wolkersdörfer1, Monika Füssel, Tobias Kiesslich, Daniel Neureiter, Frieder Berr, Daniela Aust, Gernot W Wolkersdörfer.   

Abstract

The underlying etiological cause of non-hereditary colorectal cancer has yet to be determined. The adenoma-carcinoma sequence is widely accepted, however, a sole trigger has not been specified. Therefore, we sought to further define genotypic and phenotypic parameters that could be involved in promoting a possible infection, inflammation and hyper-proliferation, followed by the adenoma-carcinoma sequence. Expression of phenotype-related parameters for MHC class I (HLA-A N-20 and β2 microglobulin) and class II (HLA-DRα and HLA-DR) as well as CD45 and carcinoembryonic antigen (CEA) were investigated immunohistochemically in a series of 93 colorectal cancers. Additionally, in 49 of the tumours the MHC class II genotype was analysed. MHC class II genotype analyses revealed a tendency towards DRB1*08 and DQB1*04. A significant association among the MHC class I markers or the MHC class II markers was found. No difference in marker expression could be detected between tumour and stromal tissue, however a significant inverse expression existed for markers of the functionally different class I or II systems. With the exception of CEA, there was no correlation between expression of any marker and tumour grade. Only 2% of tumours expressed no markers for MHC class I and II. Further studies on MHC class I and II genotype and phenotype relation in colorectal cancer may help to identify trigger mechanisms for tumourigenesis, involved markers and possible mechanisms of subsequent immune escape.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874254     DOI: 10.3892/or.2011.1427

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

Review 1.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells.

Authors:  Jin Hong Liu; Yong Mei Bian; Yi Xie; Dao Pei Lu
Journal:  Mol Med Rep       Date:  2015-03-20       Impact factor: 2.952

3.  Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.

Authors:  Peixin Chen; Lishu Zhao; Hao Wang; Liping Zhang; Wei Zhang; Jun Zhu; Jia Yu; Sha Zhao; Wei Li; Chenglong Sun; Chunyan Wu; Yayi He; Caicun Zhou
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.